Boehringer Ingelheim GmbH
Leoforos Andrea Syngrou 340, 176 73 Kallithea, Greece
Boehringer Ingelheim partners with PetMedix
Boehringer Ingelheim partners with PetMedix
- Boehringer Ingelheim has entered into a partnership with PetMedix, a UK based research and development stage biopharmaceutical company.
- Strengthening partnerships to accelerate innovation and growth is now one of the key elements of Boehringer Ingelheim’s refocused strategy.
Boehringer Ingelheim is pleased to announce a multi-year partnership with PetMedix to develop novel and transformative companion animal antibody therapeutics using PetMedix’s proprietary Ky9™ platform. As part of the collaboration, PetMedix will undertake discovery activities against a number of key targets, and Boehringer Ingelheim will work to develop and bring these therapies to market.
While there are many technologies that have been used to develop human therapeutic antibodies, PetMedix’s breakthrough approach is equivalent to one that has resulted in a number of successful, novel therapies for humans. PetMedix is the only company in the world that has brought this innovative approach to veterinary medicine, with its Ky9™ platform able to rapidly and efficiently generate fully canine therapeutic antibodies. This approach saves time and money in drug development, and reduces the risk of certain key adverse events relative to other antibody technologies.
“We are excited to be working with Boehringer Ingelheim on this project as we feel we bring complementary experience and expertise to this partnership. PetMedix has developed the leading pet antibody discovery engine, and it will be through Boehringer Ingelheim’s global scale and industry leadership that these novel therapies will best be able to succeed and ultimately benefit the animals,” said Dr Tom Weaver, CEO of PetMedix.
“Boehringer Ingelheim is pleased to be working with PetMedix on this cutting edge technology as a means to bring innovative new therapies to improve the health of animals globally. PetMedix has a unique expertise and its focus on innovation aligns well with our own,” shared James Allan, Global Head of Transaction, Business Development & Licensing, Boehringer Ingelheim Animal Health.
PetMedix™ is a Cambridge, UK based research and development stage biopharmaceutical company developing antibody-based therapeutics for companion animals. The growing team have over 30 years’ experience building platforms that can develop species-specific therapeutic antibodies.
Driven by the core value of improving the health and welfare of animals, PetMedix™ is taking the cutting edge of human medicine and using it to develop innovative new veterinary treatments against a wide range of clinical indications for dogs and for cats. https://www.petmedix.co.uk
Boehringer Ingelheim Animal Health
The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 10,000 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.
Respect for animals, humans and the environment is at the heart of what we do. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society-threatening diseases.
Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of 4 billion euros in 2019 and presence in more than 150 countries. For more information visit: www.boehringer-ingelheim.com/animal-health/overview.
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.